Yahoo Finance Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), that sends out a positive message to the company's shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
Check out our latest analysis for Xeris Biopharma Holdings
Xeris Biopharma Holdings Insider Transactions Over The Last Year
The Chief Financial Officer Steven Pieper made the biggest insider purchase in the last 12 months. That single transaction was for US$55k worth of shares at a price of US$1.95 each. That means that an insider was happy to buy shares at above the current price of US$1.75. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
Xeris Biopharma Holdings insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Xeris Biopharma Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Are Xeris Biopharma Holdings Insiders Buying Or Selling?
Over the last three months, we've seen a bit of insider buying at Xeris Biopharma Holdings. Lead Independent Director John Schmid shelled out US$9.7k for shares in that time. It's good to see the insider buying, as well as the lack of recent sellers. But in this case the amount purchased means the recent transaction may not be very meaningful on its own.
Insider Ownership Of Xeris Biopharma Holdings
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Xeris Biopharma Holdings insiders own about US$7.2m worth of shares (which is 2.8% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
So What Do The Xeris Biopharma Holdings Insider Transactions Indicate?
Our data shows a little insider buying, but no selling, in the last three months. Overall the buying isn't worth writing home about. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Xeris Biopharma Holdings insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Xeris Biopharma Holdings has 2 warning signs (1 is a bit unpleasant!) that deserve your attention before going any further with your analysis.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
